The Journal of Pain
Volume 10, Issue 9 , Pages 961-968 , September 2009

Continuous Buprenorphine Delivery Effect in Streptozotocine-Induced Painful Diabetic Neuropathy in Rats

  • Annalisa Canta

      Affiliations

    • Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Milan, Italy
    • Corresponding Author InformationAddress reprint requests to Dr Annalisa Canta, Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Via Cadore 48 – 20052 Monza (MI), Italy.
    • ,
  • Alessia Chiorazzi

      Affiliations

    • Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Milan, Italy
    • ,
  • Cristina Meregalli

      Affiliations

    • Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Milan, Italy
    • ,
  • Valentina Carozzi

      Affiliations

    • Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Milan, Italy
    • ,
  • Norberto Oggioni

      Affiliations

    • Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Milan, Italy
    • ,
  • Giuseppe Lauria

      Affiliations

    • Foundation IRCCS National Neurological Institute “Carlo Besta,” Milan, Italy
    • ,
  • Raffaella Lombardi

      Affiliations

    • Foundation IRCCS National Neurological Institute “Carlo Besta,” Milan, Italy
    • ,
  • Roberto Bianchi

      Affiliations

    • Pharmacologic Institute “Mario Negri,” Milan, Italy
    • ,
  • Carla Porretta-Serapiglia

      Affiliations

    • Pharmacologic Institute “Mario Negri,” Milan, Italy
    • ,
  • Guido Cavaletti

      Affiliations

    • Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Milan, Italy

Received 29 January 2009 ,Revised 18 March 2009 ,Accepted 2 April 2009.

References 

  1. Bannwarth B. Risk-benefit assessment of opioids in chronic noncancer pain. Drug Saf. 1999;21:283–296
  2. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A. 2004;101:823–828
  3. Bianchi R, Marini P, Merlini S, Fabris M, Triban C, Mussini E, et al. ATPase activity defects in alloxan-induced diabetic sciatic nerve recovered by ganglioside treatment. Diabetes. 1988;37:1340–1345
  4. Boger RH. Renal impairment: A challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006;20(Suppl 1):s17–s23
  5. Borgland SL. Acute opioid receptor desensitization and tolerance: Is there a link?. Clin Exp Pharmacol Physiol. 2001;28:147–154
  6. Brase DA. Is intracellular sodium involved in the mechanism of tolerance to opioid drugs?. Med Hypotheses. 1990;32:161–167
  7. Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia. 2004;47:718–724
  8. Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology. 1997;18:137–145
  9. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998;9:443–447
  10. Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain. 1993;53:81–88
  11. Cowan A. Buprenorphine: New pharmacological aspects. Int J Clin Pract Suppl. 2003;3-8:23–24
  12. Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. 1977;60:547–554
  13. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977;60:537–545
  14. Debruyne D, Quentin T, Poisnel G, Lelong-Boulouard V, Barre L, Coquerel A. Acute and chronic administration of clorazepate modifies the cell surface regulation of mu opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res. 2005;1052:222–231
  15. Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet. 1997;349:753–758
  16. Dini D, Fassio T, Gottlieb A, Gini M. [Controlled study of the analgesic effect and tolerability of buprenorphine in cancer patients]. Minerva Med. 1986;77:93–104
  17. Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials. Eur J Pain. 2006;10:667–676
  18. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63:1999–2010
  19. Freye E, Latasch L. [Development of opioid tolerance: Molecular mechanisms and clinical consequences]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2003;38:14–26
  20. Grecksch G, Bartzsch K, Widera A, Becker A, Hollt V, Koch T. Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology (Berl). 2006;186:177–184
  21. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842–1846
  22. Hsu MM, Wong CS. The roles of pain facilitatory systems in opioid tolerance. Acta Anaesthesiol Sin. 2000;38:155–166
  23. Kiguchi S, Imamura T, Ichikawa K, Kojima M. Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy. Clin Exp Pharmacol Physiol. 2004;31:57–64
  24. Kouya PF, Hao JX, Xu XJ. Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol. 2002;450:49–53
  25. Lauria G, Lombardi R, Borgna M, Penza P, Bianchi R, Savino C, et al. Intraepidermal nerve fiber density in rat foot pad: Neuropathologic-neurophysiologic correlation. J Periph Nerv Syst. 2005;10:202–208
  26. Lewis JW, Husbands SM. The orvinols and related opioids: High affinity ligands with diverse efficacy profiles. Curr Pharm Des. 2004;10:717–732
  27. Likar R, Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: Four case studies. Anesth Analg. 2005;100:781–785
  28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  29. Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain. 1998;76:151–157
  30. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain. 1995;61:353–364
  31. Masocha W, Gonzalez LG, Baeyens JM, Agil A. Mechanisms involved in morphine-induced activation of synaptosomal Na+,K+-ATPase. Brain Res. 2002;957:311–319
  32. McQuay HJ. Neuropathic pain: Evidence matters. Eur J Pain 6(Suppl A). 2002;11–18
  33. Motta EM, Calixto JB, Rae GA. Mechanical hyperalgesia induced by endothelin-1 in rats is mediated via phospholipase C, protein kinase C, and MAP kinases. Exp Biol Med (Maywood). 2006;231:1141–1145
  34. Park I, Kim D, Song J, In CH, Jeong SW, Lee SH, et al. Buprederm, a new transdermal delivery system of buprenorphine: Pharmacokinetic, efficacy and skin irritancy studies. Pharm Res. 2008;25:1052–1062
  35. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313
  36. Picard PR, Tramer MR, McQuay HJ, Moore RA. Analgesic efficacy of peripheral opioids (all except intra-articular): A qualitative systematic review of randomised controlled trials. Pain. 1997;72:309–318
  37. Radbruch L, Vielvoye-Kerkmeer A. Buprenorphine TDS: The clinical development rationale and results. Int J Clin Pract Suppl. 2003;15–18
  38. Rossano C, De Luca LF, Firetto V, Fossi F. Activity and tolerability of buprenorphine after parenteral and sublingual administration. Clin Ther. 1982;5:61–68
  39. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223–1232
  40. Sadee W, Rosenbaum JS, Herz A. Buprenorphine: Differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther. 1982;223:157–162
  41. Said G. Diabetic neuropathy: A review. Nat Clin Pract Neurol. 2007;3:331–340
  42. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother. 2005;5:315–323
  43. Sporer KA. Buprenorphine: A primer for emergency physicians. Ann Emerg Med. 2004;43:580–584
  44. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025–1030
  45. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol. 1996;16:58–67
  46. Sugimoto K, Rashid IB, Shoji M, Suda T, Yasujima M. Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. J Pain. 2008;9:237–245
  47. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000;43:957–973

 Supported in part by an unrestricted research grant from Grunenthal Italia.

PII: S1526-5900(09)00479-9

doi: 10.1016/j.jpain.2009.04.003

The Journal of Pain
Volume 10, Issue 9 , Pages 961-968 , September 2009

Article Tools

* Image Usage & Resolution